Cargando…

Adoptive immunotherapy against ovarian cancer

The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mittica, Gloria, Capellero, Sonia, Genta, Sofia, Cagnazzo, Celeste, Aglietta, Massimo, Sangiolo, Dario, Valabrega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869278/ https://www.ncbi.nlm.nih.gov/pubmed/27188274 http://dx.doi.org/10.1186/s13048-016-0236-9

Ejemplares similares

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
por: Rotolo, Ramona, et al.
Publicado: (2019)

Recent advances in the development of breast cancer vaccines
por: Milani, Andrea, et al.
Publicado: (2014)

Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2020)

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer
por: Erriquez, Jessica, et al.
Publicado: (2016)

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
por: Donini, Chiara, et al.
Publicado: (2021)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells
por: Capellero, Sonia, et al.
Publicado: (2022)

Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors
por: Sangiolo, Dario
Publicado: (2011)

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
por: Circosta, Paola, et al.
Publicado: (2022)

PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
por: D’Ambrosio, Concetta, et al.
Publicado: (2020)

Translational Research in Ovarian Cancer
por: Di Renzo, Maria Flavia, et al.
Publicado: (2020)

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022)

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
por: Merlano, Marco Carlo, et al.
Publicado: (2021)

Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
por: Iaia, Ilenia, et al.
Publicado: (2022)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
por: Turinetto, Margherita, et al.
Publicado: (2022)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
por: Montemurro, Filippo, et al.
Publicado: (2008)

The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer
por: Beumer-Chuwonpad, Ammarina, et al.
Publicado: (2021)

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
por: Gammaitoni, Loretta, et al.
Publicado: (2015)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience
por: Fenocchio, Elisabetta, et al.
Publicado: (2019)

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
por: Milanesio, Michela Camilla, et al.
Publicado: (2020)

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018)

Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment
por: Delfanti, Gloria, et al.
Publicado: (2022)

Recent advances in adoptive cancer immunotherapy in china
por: Zhou, Juhua
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3uebgtdsk4nol40a7n6tcdnhs7